#Japan #Tokyo #cancer detection #MiRNDa #RNA Modification

MiRNDa Inc.'s Journey and Its Commitment to Early Cancer Detection

MiRNDa Inc., based in Minato, Tokyo, has successfully completed its seed funding round with the backing of key investors, including the Global Brain Corporation’s Takanawa Gateway Earth Benefit Fund and Meiji Yasuda's Future Co-Creation Fund. Led by CEO Masaki Hirose, the startup was established based on research outcomes developed through the Cabinet Office's Strategic Innovation Creation Program (SIP) and has received continual support from the healthcare incubator, Premo Partners, since its inception.

The venture focuses on advancing RNA modification analysis technology, which has shown a promising diagnostic performance for early detection of cancer. With the funds acquired from this funding round, MiRNDa aims to not only bolster its presence in Japan but also to target global markets, particularly in the realm of innovative cancer screening.

The Challenge of Early Cancer Detection

In many parts of the world, late-stage cancer diagnoses remain a significant societal issue due to the lack of early detection, often leading to poorer prognoses. Cancers like pancreatic and liver cancer are especially troubling, as they often elude detection until they reach an advanced stage.

MiRNDa’s vision encapsulates the urgent need to transform this reality: "Transforming cancers that are undetectable into those that can be recognized." The company is dedicated to enabling every individual to receive timely screenings and subsequently early treatment, thereby addressing this pressing healthcare challenge.

Comments from Leadership

Masaki Hirose, CEO of MiRNDa, expressed enthusiasm for the support received from investors such as Global Brain. He articulated, “Gaining approval from our investors validates our vision and technological capabilities. Early detection of cancer significantly alters treatment choices and outcomes. Despite advances, many cancers still evade early detection, underscoring the substantial unmet medical needs.”

MiRNDa intends to leverage RNA modifications—an underutilized biomarker—through innovative analysis techniques to reshape cancer detection practices and ultimately offer solutions to patients at critical junctures in their health journeys.

The funding is anticipated to act as a significant catalyst in accelerating MiRNDa's research and clinical development, bringing RNA modification analysis techniques to the forefront of early cancer detection, not just in Japan but across the globe.

Insights from Global Brain

Taku Shigemura, an Investment Group Partner at Global Brain Corporation, shared insights into the rationale behind their investment: “In cancers like pancreatic cancer, early detection remains a challenge with significant unmet medical needs. MiRNDa approaches this substantial challenge with its unique RNA modification analysis technology. We recognized the immense potential of their technology to solve global healthcare issues, which led us to invest in their promising growth.”

Global Brain plans to leverage its extensive network and insights to support MiRNDa's growth journey alongside their limited partners, further contributing to advancements in early cancer detection.

Company Background

• - Name: MiRNDa Inc. (ミルンダ株式会社)
• - CEO: Masaki Hirose
• - Location: 9th Floor, Saka no Tsuji Square, 5-36-4 Shiba, Minato, Tokyo, 108-0014, Japan
• - Website: miRNDa.biz
• - Focus: Research and development of in vitro diagnostic pharmaceuticals and medical devices utilizing RNA modification analysis technology.

By addressing crucial gaps in cancer detection, MiRNDa stands at the forefront of potential breakthroughs that could redefine the landscape of medical diagnostics, fostering hope for earlier and more effective cancer treatment outcomes.